405:(GVHD), the most serious complication of allogeneic stem cell transplantation, and later on for treatment of CLL and multiple sclerosis. Later, Slavin introduced the concept of post-transplant depletion of host-vs-graft and graft-vs-host reactive lymphocytes with induction of bilateral transplantation tolerance. These discoveries made it possible to extend the use of allogeneic stem cell transplantation using haploidentical donors instead of fully matched donors for safer allogeneic stem cell transplantation for every patient in need with hematological malignancies and solid tumors as well as for induction of transplantation tolerance to organ allografts. In parallel, Slavin introduced new approaches for treatment of life-threatening
362:. This investment aimed to further develop new approaches based on cell therapy for the treatment of cancer, autoimmune diseases, and organ transplantation. These approaches focused on new methods for regulation rather than non-specific suppression of the immune system. As a result, Slavin’s research center was established by Baxter International, headquartered in Chicago, USA, and also supported by the Danny Cunniff Leukemia Research Center. Slavin served as the founder and director of this research center from 1994 to 2007.
303:
323:
295:
496:
Slavin's initial success applying bone marrow-derived mesenchymal stem cells (MSCs) for the treatment of neuroinflammatory and neurodegenerative disorders, together with
Professor Karussis, provided the rationale for using in vitro differentiated MSCs and possibly for future application of secretory
417:
Based on the cumulative experience using cell therapy, in recent years, Slavin and his team also focused on using multi-potential bone marrow, adipose tissue, or placenta & cord tissue-derived MSCs for regenerative medicine, pioneering the use of MSCs for the treatment of orthopedic indications
392:
In parallel with the growing activities of Slavin's center and his international impact in cell therapy, new approaches were developed for induction of transplantation tolerance of host-vs-graft and graft-vs-host towards developing improved methods for allogeneic blood or marrow transplantation as
1052:
Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bordignon C (28 June 2002). "Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning".
458:
Introducing NST and RIC made it possible to provide curative stem cell transplantation for a large number of patients in need with no lower or upper age group, including patients in poor performance status. Still, it would not be otherwise candidates for conventional myeloablative allogeneic stem
454:
using killer cells activated before and following cell infusion was translated into a new paradigm for cellular therapy of cancer based on the use of the transient circulation of non-engrafting donor lymphocytes targeted against minimal residual disease as a new approach for the potential cure of
769:
Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar C, Hale G, Waldmann H, Steinberg SM, SLAVIN S (March 1995). "T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using
Campath‐1 antibodies and
473:
Slavin applied the same principle for successful induction of transplantation tolerance to organ allografts pioneered successfully for the first recipient of kidney allograft alive and well >10 years out. Observations by Slavin's team indicating that re-induction of self-tolerance could be
373:
born with adenosine deaminase deficiency in 2002. The treated infant has remained free of disease for more than 16 years without requiring any further treatment. The same procedure was successfully used by the Milan team to treat many additional patients, all of whom were cured by gene therapy.
347:
is indicated for all patients in need. RIC or NST enables much safer curative stem cell transplantation for every patient, regardless of age, including those with less than optimal clinical conditions who would not be eligible for standard myeloablative stem cell transplantation.
311:
2083:"Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic tissues: I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specific host lymphocytes"
1411:"Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic tissues: I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specific host lymphocytes"
385:. This approach efficiently eliminates cancer while inducing long-lasting anti-cancer immunity to prevent recurrent disease. Innovative cell-mediated immunotherapy is now applied in other centers for treating otherwise resistant cancers, including patients with
505:
Slavin authored more than 600 scientific publications. He serves on many editorial boards and national and international advisory boards. He has received numerous international awards in recognition of his excellence in basic science and clinical medicine.
34:
196:
He is currently serving as the medical and scientific director of
Biotherapy International Center for Innovative Cancer Immunotherapy & Cellular Medicine in Tel Aviv, Israel, and as the medical director at Superinfection, a biotechnology company in
938:
271:(DLI) for the treatment and prevention of recurrent disease. He also pioneered the use of adaptive allogeneic cell-mediated immunotherapy and cytokine-activated lymphocytes for both treating and preventing relapse following allogeneic and autologous
434:
Slavin's primary research and clinically applied discoveries were represented in over 600 published articles and more than 900 national and international scientific presentations, resulting in global impact in several disciplines mostly related to
481:
In 1977, Slavin discovered the first animal model of B-cell leukemia/lymphoma (BCL1), which provided an opportunity to understand better the biology of B cells and to develop new therapeutic strategies based on the preclinical animal model.
2665:
Hosseini
Shamili F, Alibolandi M, Rafatpanah H, et al. (Apr 2019). "Immunomodulatory properties of MSC-derived exosomes armed with high-affinity aptamer toward mylein as a platform for reducing multiple sclerosis clinical score".
994:
282:
and led to the development of new concepts for treating hematologic malignancies and solid tumors. The focus was on utilizing well-tolerated non-myeloablative stem cell transplantation as a platform for cancer cell therapy, targeting
413:
stem cell transplantation or more recently using multi-potent mesenchymal stem cells (MSCs) for regulation of the inflammatory anti-self reactivity in neuroinflammatory and neurodegenerative disorders focusing on multiple sclerosis.
2308:"Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on the outcome"
2439:
Waldmann H, Polliak A, Hale G, Or R, et al. (Sep 1984). "Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1)".
953:"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases"
342:
transplantation (NST) was pioneered by Slavin for safer stem cell transplantation in the treatment of malignant and life-threatening non-malignant disorders that can be corrected using stem cells. Post-transplant
1199:"Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study"
741:
Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R (Dec 1995). "Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes".
478:
provided the rationale for the use of a similar approach for successful treatment of patients with life-threatening autoimmune disorders including multiple sclerosis and systemic lupus erythematosus.
287:
against chemotherapy-resistant malignant cells. Using procedures developed by Slavin and his team, cancer treatment is based on a brighter approach rather than aggressive treatment with conventional
255:, he opened the first Bone Marrow Transplantation Center at Hadassah University Hospital, which was later recognized as Israel's National Bone Marrow Transplantation and Cancer Immunotherapy Center.
2750:
2626:"Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials"
459:
cell transplantation. Using NST and RIC provided a safe approach for transplantation of patient's susceptible to conventional cytoreductive conditioning including older patients, patients with
291:. This approach is associated with reduced immediate and late procedure-related toxicity and mortality, aiming at the selective elimination of all malignant cells, including cancer stem cells.
991:
470:
by Slavin's team made it possible to provide a relatively safe and non-expensive transplant procedure for patients with no matched donor available using a haploidentical family member.
1733:
Kurkalli BG, Gurevitch O, Sosnik A, Cohn D, Slavin S (Mar 2010). "Repair of bone defect using bone marrow cells and demineralized bone matrix supplemented with polymeric materials".
2745:
489:, Slavin was the first to introduce the use of an anti-CD52 monoclonal antibody (CAMPATH-1; Alemtuzumab and currently Lemtrada) that was initially used by Slavin for prevention of
951:
Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (Feb 1998).
1993:"Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia"
2212:
Burt RK, Slavin S, Burns WH, Marmont AM (Aug 2002). "Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?".
1573:
Slavin S (Jul 1993). "Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning".
939:
Nonmyeloablative conditioning in preparation for allogeneic stem cell transplantation: the future treatment of choice of hematologic malignancies and genetic diseases
815:"Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation"
2347:
Strober S, Gronowicz ES, Knapp MR, Slavin S, Vitetta ES, Warnke RA, Kotzin B, Schröder J (1979). "Immunobiology of a spontaneous murine B cell leukemia (BCL1)".
2124:"Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients"
1780:"Human Peripheral Blood Mononuclear Cells Incubated in Vasculogenic Conditioning Medium Dramatically Improve Ischemia/Reperfusion Acute Kidney Injury in Mice"
1870:"A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation"
493:(GVHD) and subsequently by others for prevention and treatment of allograft rejection and subsequently approved by FDA for treatment of multiple sclerosis.
1952:"Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors"
1493:"Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models"
895:
Slavin S (Jul 2004). "Smarter rather than stronger treatment of hematological malignancies and non-malignant indications for stem-cell transplantation".
90:
Medical
Director of Biotherapy International, The Center for Innovative Cancer Biotherapy & Regenerative Medicine, medical director at Superinfection
1643:
Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S (Feb 2011).
1396:
418:
including cartilage repair and new bone formation as well as for repair of renal function in addition to continuous treatment of neuroinflammatory,
1600:
Karussis D, Slavin S (Aug 2004). "Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures".
1645:"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis"
1827:
Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (Sep 2000).
1534:"Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning"
237:
229:
80:
76:
1297:"Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody"
475:
393:
well as transplantation of cellular and perfused organ allografts. Initially, Slavin pioneered the use of monoclonal antibodies anti-CD52 (
2042:"Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease"
562:
588:
570:
548:
526:
2760:
2165:"Depletion of alloreactive T cells for tolerance induction in a recipient of kidney and hematopoietic stem cell transplantations"
370:
2740:
222:
214:
72:
2163:
Tangnararatchakit K, Tirapanich W, Anurathapan U, Tapaneya-Olarn W, Pakakasama S, Jootar S, Slavin S, Hongeng S (May 2012).
1829:"Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation"
1694:"Reconstruction of cartilage, bone, and hematopoietic microenvironment with demineralized bone matrix and bone marrow cells"
696:
2575:"Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings"
386:
717:
1147:"Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency"
2526:"Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up"
2485:"Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years"
1256:"Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes"
163:
1909:
Shapira MY, Resnick IB, Bitan M, Ackerstein A, Samuel S, Elad S, Miron S, Zilberman I, Slavin S, Or R (Jul 2004).
1868:
Shapira MY, Or R, Resnick IB, Bitan M, Ackerstein A, Samuel S, Elad S, Zilberman I, Miron S, Slavin S (Sep 2003).
1452:"Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice"
490:
419:
268:
159:
359:
171:
2755:
631:
423:
334:
focuses on a two-step approach: tumor debulking using conventional and innovative modalities, followed by
1145:
Kohn DB, Hershfield MS, Puck JM, Aiuti A, Blincoe A, Gaspar HB, Notarangelo LD, Grunebaum E (Mar 2019).
402:
382:
366:
298:
Slavin with
Russian pathophysiologist Sukhikh at the International Oncology conference in Moscow in 2017
190:
186:
113:
443:
made it possible to treat otherwise resistant hematological malignancies and specific metastatic solid
2735:
1062:
813:
Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R (Mar 1996).
351:
264:
228:
From 1975 to 1978, Slavin trained in clinical immunology/rheumatology at the
Division of Immunology,
105:
1950:
Bitan M, Or R, Shapira MY, Aker M, Resnick IB, Ackerstein A, Samuel S, Elad S, Slavin S (Jul 2006).
770:
post‐transplant administration of donor's peripheral blood lymphocytes for prevention of relapse".
460:
331:
127:
109:
338:
of minimal residual disease. Innovative reduced-intensity conditioning (RIC) or non-myeloablative
2691:
2555:
2465:
2372:
2237:
2194:
1625:
1236:
1086:
920:
831:
814:
795:
381:, focusing on the use of activated donor lymphocytes targeted against cancer with monoclonal and
245:
1911:"Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients"
2683:
2647:
2606:
2547:
2506:
2457:
2421:
2364:
2329:
2288:
2229:
2186:
2145:
2104:
2063:
2022:
1973:
1932:
1891:
1850:
1809:
1760:
1715:
1674:
1617:
1582:
1555:
1514:
1473:
1432:
1379:
1318:
1277:
1228:
1197:
Slavin S, Ackerstein A, Or R, Shapira MY, Gesundheit B, Askenasy N, Morecki S (October 2010).
1176:
1127:
1078:
974:
912:
874:
836:
787:
751:
584:
566:
544:
522:
315:
233:
123:
1335:
466:
Later on, introducing the concept of post-transplant deletion of alloreactive lymphocytes by
217:
and was awarded his medical degree in 1967. He served as a doctor in the
Frogman Unit of the
2675:
2637:
2596:
2586:
2537:
2496:
2449:
2411:
2403:
2356:
2319:
2278:
2268:
2221:
2176:
2135:
2094:
2053:
2012:
2004:
1963:
1922:
1881:
1840:
1799:
1791:
1750:
1742:
1705:
1664:
1656:
1609:
1545:
1504:
1463:
1422:
1369:
1361:
1308:
1267:
1218:
1210:
1166:
1158:
1117:
1070:
1032:
1024:
964:
904:
866:
826:
779:
467:
2392:"In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins"
2524:
Clatworthy MR, Friend PJ, Calne RY, Rebello PR, Hale G, Waldmann H, Watson CJ (Apr 2009).
998:
486:
310:
1223:
1198:
1066:
221:
until 1970. From 1970 to 1975, he trained at the
Department of Internal Medicine at the
2710:"Shimon SLAVIN International Center for Cell Therapy & Cancer Immunotherapy (CTCI)"
2601:
2574:
2416:
2391:
2360:
2017:
1992:
1804:
1779:
1669:
1644:
1374:
1349:
1171:
1146:
1037:
1012:
783:
410:
302:
2453:
1509:
1492:
1468:
1451:
908:
870:
2729:
2709:
2501:
2484:
2181:
2164:
2099:
2082:
1427:
1410:
1104:
Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, et al. (Jan 2009).
378:
344:
335:
151:
2695:
2559:
2469:
2241:
2198:
1692:
Gurevitch O, Kurkalli BG, Prigozhina T, Kasir J, Gaft A, Slavin S (September 2003).
1629:
1240:
1090:
924:
799:
439:
for treating malignant and nonmalignant disorders. Immunotherapy of cancer by donor
2376:
436:
406:
355:
288:
284:
279:
218:
167:
2679:
656:
581:
Non-myeloablative Stem Cell
Transplantation (NST). New Frontiers in Cancer Therapy
369:
in Milan to pioneer the first successful use of gene therapy for the treatment of
33:
2642:
2625:
1550:
1533:
1491:
Prigozhina TB, Gurevitch O, Morecki S, Yakovlev E, Elkin G, Slavin S (Jan 2002).
1313:
1296:
857:
Slavin S (August 2001). "Immunotherapy of cancer with alloreactive lymphocytes".
2542:
2525:
1845:
1828:
1660:
676:
394:
175:
155:
2040:
Nagler A, Ackerstein A, Kapelushnik J, Or R, Naparstek E, Slavin S (Aug 1999).
1968:
1951:
1746:
1710:
1693:
1272:
1255:
1162:
358:
and signed an agreement that resulted in significant investment with Slavin at
2324:
2307:
2273:
2256:
2140:
2123:
1613:
1214:
451:
440:
179:
2591:
2008:
1795:
657:"Prof. Slavin, Medical & Scientific Director of Biotherapy International"
232:. In 1978, he trained in clinical bone marrow transplantation under the late
1074:
1028:
969:
952:
608:
339:
272:
252:
2687:
2651:
2610:
2551:
2510:
2407:
2333:
2292:
2233:
2190:
2149:
2067:
2058:
2041:
2026:
1977:
1936:
1927:
1910:
1895:
1886:
1869:
1854:
1813:
1764:
1719:
1678:
1621:
1559:
1518:
1477:
1383:
1322:
1295:
Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S (Aug 2008).
1281:
1232:
1180:
1131:
1082:
916:
878:
322:
294:
2461:
2425:
2108:
1586:
1436:
1122:
1105:
978:
840:
791:
755:
537:
Tolerance in Bone Marrow and Organ Transplantation: Achievements and Goals
326:
Slavin with Baby Salsabil. First successful treatment for 'bubble babies'.
2368:
1106:"Gene therapy for immunodeficiency due to adenosine deaminase deficiency"
604:
540:
518:
444:
198:
57:
2573:
Barclay K, Carruthers R, Traboulsee A, Bass AD, et al. (Mar 2019).
1991:
Ayas M, Saber W, Davies SM, Harris RE, Hale GA, et al. (May 2013).
1365:
2225:
1755:
611:
between 1946 and 2007. Slavin is married and father of three children.
306:
Meeting with Zaza Sopromadze, Deputy Minister of Health Georgia in 2017
241:
202:
193:
for the treatment of neurological, systemic, and orthopedic disorders.
131:
2283:
147:
61:
1254:
Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S (Feb 2006).
2483:
Watson CJ, Bradley JA, Friend PJ, Firth J, et al. (Jun 2005).
321:
309:
301:
293:
2624:
Petrou P, Gothelf Y, Argov Z, Gotkine M, et al. (Mar 2016).
2257:"Hematopoietic stem cell transplantation for multiple sclerosis"
697:"Israeli cell therapy tricks immune system into fighting cancer"
497:
products of MSCs, such as extracellular vesicles and exosomes.
275:
transplantation for hematologic malignancies and solid tumors.
2255:
Burt RK, Cohen B, Rose J, Petersen F, et al. (Jun 2005).
1397:
FDA Approves Lemtrada™ (alemtuzumab) for Relapsing MS - UPDATE
398:
185:
More recently, he has been working on the use of multi-potent
2306:
Burt RK, Han X, Gozdziak P, Yaung K, et al. (Jun 2018).
515:
Bone Marrow and Organ Transplantation: Achievements and Goals
1013:"Scientists use gene therapy to cure immune deficient child"
1336:
Triple Negative Breast Cancer: a Highly Significant Finding
365:
Slavin, along with his team, used a vector provided by the
377:
More recently, Slavin introduced personalized anti-cancer
1778:
Ohtake T, Kobayashi S, Slavin S, et al. (Mar 2018).
278:
These observations confirmed the therapeutic benefits of
2122:
Granata A, Fürst S, Bramanti S, et al. (Mar 2019).
2081:
Prigozhina TB, Gurevitch O, Zhu J, Slavin S (May 1997).
1532:
Prigozhina TB, Elkin G, Khitrin S, Slavin S (Nov 2004).
1409:
Prigozhina TB, Gurevitch O, Zhu J, Slavin S (May 1997).
937:
Slavin S, Napier A, Naparstek E, Kapelushnik J et al.,
450:
The unique efficacy of intentionally mismatched donor
2390:
Krolick KA, Uhr JW, Slavin S, Vitetta ES (Jun 1982).
1450:
Prigozhina TB, Gurevitch O, Slavin S (October 1999).
2751:
The Hebrew University-Hadassah Medical School alumni
213:
Slavin graduated from the School of Medicine at the
119:
101:
86:
68:
40:
21:
1348:Fraser G, Smith CA, Imrie K, Meyer R (Jun 2007).
474:induced by lymphoablative treatment followed by
263:In early 1987, Slavin introduced the concept of
2746:Stanford University School of Medicine alumni
1350:"Alemtuzumab in chronic lymphocytic leukemia"
447:in patients with multidrug-resistant cancer.
8:
832:10.1182/blood.V87.6.2195.bloodjournal8762195
1192:
1190:
992:Danny Cunniff Leukemia Research Laboratory
890:
888:
583:. Darwin Scientific Publishing Ltd. 2000.
32:
18:
2641:
2600:
2590:
2541:
2500:
2415:
2323:
2282:
2272:
2180:
2139:
2098:
2057:
2016:
1967:
1926:
1885:
1844:
1803:
1754:
1709:
1668:
1549:
1508:
1467:
1426:
1373:
1312:
1271:
1222:
1170:
1121:
1036:
968:
852:
850:
830:
718:"Opening a door to regenerative medicine"
455:cancer at an early stage of the disease.
509:Shimon Slavin also authored four books:
620:
174:to induce transplantation tolerance to
238:Fred Hutchinson Cancer Research Center
230:Stanford University School of Medicine
81:Fred Hutchinson Cancer Research Center
77:Stanford University School of Medicine
1399:, National Multiple Sclerosis Society
677:"Leadership - Superinfection Therapy"
626:
624:
318:, the last leader of the Soviet Union
7:
476:autologous stem cell transplantation
409:diseases based on either autologous
150:professor of medicine. He pioneered
463:and chronic granulomatous disease.
2361:10.1111/j.1600-065X.1979.tb00303.x
1011:Siegel-Itzkovich J (6 July 2002).
784:10.1111/j.1365-2141.1995.tb08356.x
563:International Atomic Energy Agency
559:The Radiological Accident in Soreq
14:
2502:10.1111/j.1600-6143.2005.00822.x
2182:10.1111/j.1399-3046.2012.01701.x
2100:10.1097/00007890-199705270-00004
1428:10.1097/00007890-199705270-00004
1203:Cancer Immunology, Immunotherapy
1833:New England Journal of Medicine
401:as Lemtrada) for prevention of
772:British Journal of Haematology
223:Hebrew University of Jerusalem
215:Hebrew University of Jerusalem
73:Hebrew University of Jerusalem
1:
2680:10.1016/j.jconrel.2019.02.032
2454:10.1016/S0140-6736(84)92564-9
1510:10.1016/S0301-472X(01)00759-7
1469:10.1016/S0301-472X(99)00088-0
909:10.1016/S0140-6736(04)16652-X
871:10.1016/S1470-2045(01)00455-7
387:triple negative breast cancer
154:mediated by allogeneic donor
16:Israeli professor of medicine
2643:10.1001/jamaneurol.2015.4321
1956:Biol Blood Marrow Transplant
1551:10.1016/j.exphem.2004.07.017
1314:10.1016/j.exphem.2008.03.005
354:recognized the potential of
2543:10.1097/TP.0b013e31819d3353
1846:10.1056/NEJM200009143431101
1661:10.1001/archneurol.2010.248
1575:Bone Marrow Transplantation
420:neurodegenerative disorders
209:Education and clinical work
158:and innovative methods for
2777:
1969:10.1016/j.bbmt.2006.03.002
1747:10.2174/157488810790442831
1711:10.1634/stemcells.21-5-588
1273:10.1182/blood-2005-07-2738
1163:10.1016/j.jaci.2018.08.024
1001:, Hadassah Medical Center.
603:Shimon Slavin was born in
269:donor lymphocytes infusion
164:hematological malignancies
2325:10.1038/s41409-018-0173-x
2274:10.1001/archneur.62.6.860
2141:10.1038/s41409-019-0500-x
1614:10.1016/j.jns.2004.04.021
1215:10.1007/s00262-010-0878-1
632:"Prof. Shimon Slavin, MD"
491:graft-versus-host disease
160:stem cell transplantation
146:(born 17 May 1941) is an
137:
94:
31:
2592:10.3389/fneur.2019.00253
2009:10.1200/JCO.2012.45.9719
1796:10.1177/0963689717753186
430:Scientific contributions
259:Clinical accomplishments
172:hematopoietic stem cells
2761:Academics from Tel Aviv
1735:Curr Stem Cell Res Ther
1538:Experimental Hematology
1497:Experimental Hematology
1456:Experimental Hematology
1301:Experimental Hematology
1075:10.1126/science.1070104
1029:10.1136/bmj.325.7354.10
970:10.1182/blood.V91.3.756
744:Experimental Hematology
360:Hadassah Medical Center
2579:Frontiers in Neurology
2408:10.1084/jem.155.6.1797
2312:Bone Marrow Transplant
2128:Bone Marrow Transplant
2059:10.1038/sj.bmt.1701903
2046:Bone Marrow Transplant
1928:10.1038/sj.bmt.1704540
1915:Bone Marrow Transplant
1887:10.1038/sj.bmt.1704190
1874:Bone Marrow Transplant
1151:J Allergy Clin Immunol
607:in 1941, but lived in
424:neurological disorders
327:
319:
307:
299:
187:mesenchymal stem cells
2741:Israeli immunologists
1123:10.1056/NEJMoa0805817
403:graft-vs-host disease
383:bispecific antibodies
367:San Raffaele Hospital
325:
313:
305:
297:
191:regenerative medicine
114:regenerative medicine
1784:Cell Transplantation
636:Open Health Alliance
352:Baxter International
265:cancer immunotherapy
106:Cancer immunotherapy
1366:10.3747/co.2007.118
1067:2002Sci...296.2410A
1061:(5577): 2410–2413.
859:The Lancet Oncology
332:treatment of cancer
128:clinical immunology
110:clinical immunology
2226:10.1007/bf03165251
2169:Pediatr Transplant
997:2019-04-24 at the
722:The Jerusalem Post
485:Together with Dr.
397:, now approved by
328:
320:
308:
300:
251:Upon returning to
2668:J Control Release
2134:(11): 1730–1737.
1544:(11): 1110–1117.
1462:(10): 1503–1510.
1421:(10): 1394–1399.
1209:(10): 1511–1519.
316:Mikhail Gorbachev
141:
140:
124:Internal medicine
2768:
2720:
2719:
2717:
2716:
2706:
2700:
2699:
2662:
2656:
2655:
2645:
2621:
2615:
2614:
2604:
2594:
2570:
2564:
2563:
2545:
2521:
2515:
2514:
2504:
2480:
2474:
2473:
2436:
2430:
2429:
2419:
2402:(6): 1797–1809.
2387:
2381:
2380:
2344:
2338:
2337:
2327:
2303:
2297:
2296:
2286:
2276:
2252:
2246:
2245:
2209:
2203:
2202:
2184:
2175:(8): E342–E347.
2160:
2154:
2153:
2143:
2119:
2113:
2112:
2102:
2078:
2072:
2071:
2061:
2037:
2031:
2030:
2020:
1988:
1982:
1981:
1971:
1947:
1941:
1940:
1930:
1906:
1900:
1899:
1889:
1865:
1859:
1858:
1848:
1824:
1818:
1817:
1807:
1775:
1769:
1768:
1758:
1730:
1724:
1723:
1713:
1689:
1683:
1682:
1672:
1640:
1634:
1633:
1597:
1591:
1590:
1570:
1564:
1563:
1553:
1529:
1523:
1522:
1512:
1488:
1482:
1481:
1471:
1447:
1441:
1440:
1430:
1406:
1400:
1394:
1388:
1387:
1377:
1345:
1339:
1333:
1327:
1326:
1316:
1292:
1286:
1285:
1275:
1266:(4): 1564–1569.
1251:
1245:
1244:
1226:
1194:
1185:
1184:
1174:
1142:
1136:
1135:
1125:
1101:
1095:
1094:
1049:
1043:
1042:
1040:
1008:
1002:
989:
983:
982:
972:
948:
942:
935:
929:
928:
892:
883:
882:
854:
845:
844:
834:
825:(6): 2195–2204.
810:
804:
803:
766:
760:
759:
738:
732:
731:
729:
728:
714:
708:
707:
705:
704:
693:
687:
686:
684:
683:
673:
667:
666:
664:
663:
653:
647:
646:
644:
643:
628:
594:
576:
554:
532:
468:cyclophosphamide
461:Fanconi's anemia
437:cellular therapy
54:
50:
48:
36:
19:
2776:
2775:
2771:
2770:
2769:
2767:
2766:
2765:
2726:
2725:
2724:
2723:
2714:
2712:
2708:
2707:
2703:
2664:
2663:
2659:
2623:
2622:
2618:
2572:
2571:
2567:
2530:Transplantation
2523:
2522:
2518:
2489:Am J Transplant
2482:
2481:
2477:
2448:(8401): 483–6.
2438:
2437:
2433:
2389:
2388:
2384:
2346:
2345:
2341:
2305:
2304:
2300:
2254:
2253:
2249:
2211:
2210:
2206:
2162:
2161:
2157:
2121:
2120:
2116:
2087:Transplantation
2080:
2079:
2075:
2039:
2038:
2034:
2003:(13): 1669–76.
1990:
1989:
1985:
1949:
1948:
1944:
1908:
1907:
1903:
1867:
1866:
1862:
1826:
1825:
1821:
1777:
1776:
1772:
1732:
1731:
1727:
1691:
1690:
1686:
1655:(10): 1187–94.
1642:
1641:
1637:
1599:
1598:
1594:
1572:
1571:
1567:
1531:
1530:
1526:
1490:
1489:
1485:
1449:
1448:
1444:
1415:Transplantation
1408:
1407:
1403:
1395:
1391:
1347:
1346:
1342:
1334:
1330:
1307:(8): 997–1003.
1294:
1293:
1289:
1253:
1252:
1248:
1196:
1195:
1188:
1144:
1143:
1139:
1103:
1102:
1098:
1051:
1050:
1046:
1010:
1009:
1005:
999:Wayback Machine
990:
986:
950:
949:
945:
936:
932:
894:
893:
886:
856:
855:
848:
812:
811:
807:
768:
767:
763:
750:(14): 1553–62.
740:
739:
735:
726:
724:
716:
715:
711:
702:
700:
695:
694:
690:
681:
679:
675:
674:
670:
661:
659:
655:
654:
650:
641:
639:
630:
629:
622:
617:
601:
591:
579:
573:
557:
551:
535:
529:
513:
503:
487:Herman Waldmann
432:
261:
211:
170:. He also used
120:Sub-specialties
64:
55:
52:
46:
44:
27:
24:
17:
12:
11:
5:
2774:
2772:
2764:
2763:
2758:
2753:
2748:
2743:
2738:
2728:
2727:
2722:
2721:
2701:
2657:
2616:
2565:
2516:
2495:(6): 1347–53.
2475:
2431:
2382:
2339:
2318:(6): 692–700.
2298:
2247:
2204:
2155:
2114:
2093:(10): 1394–9.
2073:
2032:
1983:
1942:
1901:
1860:
1819:
1790:(3): 520–530.
1770:
1725:
1684:
1635:
1592:
1565:
1524:
1483:
1442:
1401:
1389:
1340:
1328:
1287:
1246:
1186:
1157:(3): 852–863.
1137:
1116:(5): 447–458.
1096:
1044:
1003:
984:
963:(3): 756–763.
943:
941:, ResearchGate
930:
884:
865:(8): 491–498.
846:
805:
778:(3): 506–515.
761:
733:
709:
688:
668:
648:
619:
618:
616:
613:
600:
597:
596:
595:
589:
577:
571:
555:
549:
533:
527:
502:
499:
431:
428:
422:and traumatic
260:
257:
210:
207:
139:
138:
135:
134:
121:
117:
116:
103:
99:
98:
96:Medical career
92:
91:
88:
84:
83:
70:
66:
65:
56:
42:
38:
37:
29:
28:
25:
22:
15:
13:
10:
9:
6:
4:
3:
2:
2773:
2762:
2759:
2757:
2756:Living people
2754:
2752:
2749:
2747:
2744:
2742:
2739:
2737:
2734:
2733:
2731:
2711:
2705:
2702:
2697:
2693:
2689:
2685:
2681:
2677:
2673:
2669:
2661:
2658:
2653:
2649:
2644:
2639:
2636:(3): 337–44.
2635:
2631:
2627:
2620:
2617:
2612:
2608:
2603:
2598:
2593:
2588:
2584:
2580:
2576:
2569:
2566:
2561:
2557:
2553:
2549:
2544:
2539:
2536:(7): 1092–5.
2535:
2531:
2527:
2520:
2517:
2512:
2508:
2503:
2498:
2494:
2490:
2486:
2479:
2476:
2471:
2467:
2463:
2459:
2455:
2451:
2447:
2443:
2435:
2432:
2427:
2423:
2418:
2413:
2409:
2405:
2401:
2397:
2393:
2386:
2383:
2378:
2374:
2370:
2366:
2362:
2358:
2354:
2350:
2343:
2340:
2335:
2331:
2326:
2321:
2317:
2313:
2309:
2302:
2299:
2294:
2290:
2285:
2280:
2275:
2270:
2266:
2262:
2258:
2251:
2248:
2243:
2239:
2235:
2231:
2227:
2223:
2219:
2215:
2214:Int J Hematol
2208:
2205:
2200:
2196:
2192:
2188:
2183:
2178:
2174:
2170:
2166:
2159:
2156:
2151:
2147:
2142:
2137:
2133:
2129:
2125:
2118:
2115:
2110:
2106:
2101:
2096:
2092:
2088:
2084:
2077:
2074:
2069:
2065:
2060:
2055:
2052:(3): 339–42.
2051:
2047:
2043:
2036:
2033:
2028:
2024:
2019:
2014:
2010:
2006:
2002:
1998:
1994:
1987:
1984:
1979:
1975:
1970:
1965:
1961:
1957:
1953:
1946:
1943:
1938:
1934:
1929:
1924:
1920:
1916:
1912:
1905:
1902:
1897:
1893:
1888:
1883:
1880:(6): 557–61.
1879:
1875:
1871:
1864:
1861:
1856:
1852:
1847:
1842:
1839:(11): 750–8.
1838:
1834:
1830:
1823:
1820:
1815:
1811:
1806:
1801:
1797:
1793:
1789:
1785:
1781:
1774:
1771:
1766:
1762:
1757:
1752:
1748:
1744:
1740:
1736:
1729:
1726:
1721:
1717:
1712:
1707:
1704:(5): 588–97.
1703:
1699:
1695:
1688:
1685:
1680:
1676:
1671:
1666:
1662:
1658:
1654:
1650:
1646:
1639:
1636:
1631:
1627:
1623:
1619:
1615:
1611:
1607:
1603:
1596:
1593:
1588:
1584:
1580:
1576:
1569:
1566:
1561:
1557:
1552:
1547:
1543:
1539:
1535:
1528:
1525:
1520:
1516:
1511:
1506:
1502:
1498:
1494:
1487:
1484:
1479:
1475:
1470:
1465:
1461:
1457:
1453:
1446:
1443:
1438:
1434:
1429:
1424:
1420:
1416:
1412:
1405:
1402:
1398:
1393:
1390:
1385:
1381:
1376:
1371:
1367:
1363:
1360:(3): 96–109.
1359:
1355:
1351:
1344:
1341:
1338:, MossReports
1337:
1332:
1329:
1324:
1320:
1315:
1310:
1306:
1302:
1298:
1291:
1288:
1283:
1279:
1274:
1269:
1265:
1261:
1257:
1250:
1247:
1242:
1238:
1234:
1230:
1225:
1220:
1216:
1212:
1208:
1204:
1200:
1193:
1191:
1187:
1182:
1178:
1173:
1168:
1164:
1160:
1156:
1152:
1148:
1141:
1138:
1133:
1129:
1124:
1119:
1115:
1111:
1107:
1100:
1097:
1092:
1088:
1084:
1080:
1076:
1072:
1068:
1064:
1060:
1056:
1048:
1045:
1039:
1034:
1030:
1026:
1022:
1018:
1014:
1007:
1004:
1000:
996:
993:
988:
985:
980:
976:
971:
966:
962:
958:
954:
947:
944:
940:
934:
931:
926:
922:
918:
914:
910:
906:
902:
898:
891:
889:
885:
880:
876:
872:
868:
864:
860:
853:
851:
847:
842:
838:
833:
828:
824:
820:
816:
809:
806:
801:
797:
793:
789:
785:
781:
777:
773:
765:
762:
757:
753:
749:
745:
737:
734:
723:
719:
713:
710:
698:
692:
689:
678:
672:
669:
658:
652:
649:
637:
633:
627:
625:
621:
614:
612:
610:
606:
599:Personal life
598:
592:
590:9781903557006
586:
582:
578:
574:
572:9789201016935
568:
564:
560:
556:
552:
550:9780444805577
546:
542:
538:
534:
530:
528:9780444805560
524:
520:
516:
512:
511:
510:
507:
500:
498:
494:
492:
488:
483:
479:
477:
471:
469:
464:
462:
456:
453:
448:
446:
442:
438:
429:
427:
425:
421:
415:
412:
411:hematopoietic
408:
404:
400:
396:
390:
388:
384:
380:
379:immunotherapy
375:
372:
368:
363:
361:
357:
353:
349:
346:
345:immunotherapy
341:
337:
336:immunotherapy
333:
324:
317:
312:
304:
296:
292:
290:
286:
281:
276:
274:
270:
266:
258:
256:
254:
249:
247:
243:
239:
235:
231:
226:
224:
220:
216:
208:
206:
204:
200:
194:
192:
188:
183:
181:
177:
173:
169:
165:
161:
157:
153:
152:immunotherapy
149:
145:
144:Shimon Slavin
136:
133:
129:
125:
122:
118:
115:
111:
107:
104:
100:
97:
93:
89:
87:Occupation(s)
85:
82:
79:
78:
74:
71:
67:
63:
59:
53:(age 83)
43:
39:
35:
30:
26:Shimon Slavin
20:
2713:. Retrieved
2704:
2671:
2667:
2660:
2633:
2629:
2619:
2585:(253): 253.
2582:
2578:
2568:
2533:
2529:
2519:
2492:
2488:
2478:
2445:
2441:
2434:
2399:
2395:
2385:
2352:
2348:
2342:
2315:
2311:
2301:
2267:(6): 860–4.
2264:
2260:
2250:
2217:
2213:
2207:
2172:
2168:
2158:
2131:
2127:
2117:
2090:
2086:
2076:
2049:
2045:
2035:
2000:
1997:J Clin Oncol
1996:
1986:
1962:(7): 712–8.
1959:
1955:
1945:
1921:(2): 155–9.
1918:
1914:
1904:
1877:
1873:
1863:
1836:
1832:
1822:
1787:
1783:
1773:
1741:(1): 49–56.
1738:
1734:
1728:
1701:
1697:
1687:
1652:
1648:
1638:
1608:(1): 59–64.
1605:
1602:J Neurol Sci
1601:
1595:
1578:
1574:
1568:
1541:
1537:
1527:
1503:(1): 89–96.
1500:
1496:
1486:
1459:
1455:
1445:
1418:
1414:
1404:
1392:
1357:
1353:
1343:
1331:
1304:
1300:
1290:
1263:
1259:
1249:
1206:
1202:
1154:
1150:
1140:
1113:
1110:N Engl J Med
1109:
1099:
1058:
1054:
1047:
1023:(7354): 10.
1020:
1016:
1006:
987:
960:
956:
946:
933:
903:(8): 122–4.
900:
896:
862:
858:
822:
818:
808:
775:
771:
764:
747:
743:
736:
725:. Retrieved
721:
712:
701:. Retrieved
699:. 2004-08-08
691:
680:. Retrieved
671:
660:. Retrieved
651:
640:. Retrieved
635:
602:
580:
558:
536:
514:
508:
504:
501:Bibliography
495:
484:
480:
472:
465:
457:
449:
433:
416:
391:
376:
364:
356:cell therapy
350:
329:
314:Slavin with
289:chemotherapy
285:killer cells
280:cell therapy
277:
262:
250:
227:
219:Israeli Navy
212:
195:
184:
168:solid tumors
143:
142:
95:
75:
51:May 17, 1941
2736:1941 births
2674:: 149–164.
2630:JAMA Neurol
2349:Immunol Rev
2261:Arch Neurol
1756:11336/14218
1649:Arch Neurol
1581:(1): 85–8.
452:lymphocytes
441:lymphocytes
395:Alemtuzumab
371:bubble baby
330:As a rule,
234:E.D. Thomas
176:bone marrow
156:lymphocytes
2730:Categories
2715:2023-05-17
2355:: 169–95.
2284:1765/63790
2220:: 226–47.
1698:Stem Cells
1354:Curr Oncol
897:The Lancet
727:2023-05-17
703:2023-05-17
682:2023-05-17
662:2023-05-17
642:2024-06-19
638:(in Greek)
615:References
407:autoimmune
246:Washington
189:(MSCs) in
180:allografts
178:and organ
102:Profession
47:1941-05-17
2396:J Exp Med
609:Jerusalem
340:stem cell
273:stem cell
253:Jerusalem
69:Education
23:Professor
2696:73501937
2688:30807806
2652:26751635
2611:30967831
2560:37851876
2552:19352132
2511:15888040
2470:45854723
2334:29855561
2293:15956156
2242:33358121
2234:12430858
2199:11281960
2191:22553996
2150:30890770
2068:10455377
2027:23547077
1978:16785060
1937:15235577
1896:12953126
1855:10984562
1814:29737200
1765:19807659
1720:12968113
1679:20937945
1630:23438663
1622:15261562
1560:15539090
1519:11823042
1478:10517491
1384:17593982
1323:18495330
1282:16234351
1241:23443095
1233:20563804
1224:11031035
1181:30194989
1132:19179314
1091:32435671
1083:12089448
995:Archived
925:40166296
917:15246713
879:11905725
800:23981575
605:Tel Aviv
565:. 1993.
543:. 1985.
541:Elsevier
521:. 1984.
519:Elsevier
199:Budapest
162:to cure
58:Tel Aviv
2602:6439479
2462:6147548
2426:6804591
2417:2186702
2377:1133666
2109:9175799
2018:3635221
1805:6038042
1670:3036569
1587:8104072
1437:9175799
1375:1899355
1172:6688493
1063:Bibcode
1055:Science
1038:1123542
979:9446633
841:8630379
792:7734348
756:8542946
242:Seattle
236:at the
203:Hungary
148:Israeli
132:allergy
2694:
2686:
2650:
2609:
2599:
2558:
2550:
2509:
2468:
2460:
2442:Lancet
2424:
2414:
2375:
2369:121100
2367:
2332:
2291:
2240:
2232:
2197:
2189:
2148:
2107:
2066:
2025:
2015:
1976:
1935:
1894:
1853:
1812:
1802:
1763:
1718:
1677:
1667:
1628:
1620:
1585:
1558:
1517:
1476:
1435:
1382:
1372:
1321:
1280:
1239:
1231:
1221:
1179:
1169:
1130:
1089:
1081:
1035:
977:
923:
915:
877:
839:
798:
790:
754:
587:
569:
547:
525:
445:tumors
267:using
62:Israel
2692:S2CID
2556:S2CID
2466:S2CID
2373:S2CID
2238:S2CID
2195:S2CID
1626:S2CID
1260:Blood
1237:S2CID
1087:S2CID
957:Blood
921:S2CID
819:Blood
796:S2CID
2684:PMID
2648:PMID
2607:PMID
2548:PMID
2507:PMID
2458:PMID
2422:PMID
2365:PMID
2330:PMID
2289:PMID
2230:PMID
2187:PMID
2146:PMID
2105:PMID
2064:PMID
2023:PMID
1974:PMID
1933:PMID
1892:PMID
1851:PMID
1810:PMID
1761:PMID
1716:PMID
1675:PMID
1618:PMID
1583:PMID
1556:PMID
1515:PMID
1474:PMID
1433:PMID
1380:PMID
1319:PMID
1278:PMID
1229:PMID
1177:PMID
1128:PMID
1079:PMID
975:PMID
913:PMID
875:PMID
837:PMID
788:PMID
752:PMID
585:ISBN
567:ISBN
545:ISBN
523:ISBN
166:and
130:and
41:Born
2676:doi
2672:299
2638:doi
2597:PMC
2587:doi
2538:doi
2497:doi
2450:doi
2446:324
2412:PMC
2404:doi
2400:155
2357:doi
2320:doi
2279:hdl
2269:doi
2222:doi
2177:doi
2136:doi
2095:doi
2054:doi
2013:PMC
2005:doi
1964:doi
1923:doi
1882:doi
1841:doi
1837:343
1800:PMC
1792:doi
1751:hdl
1743:doi
1706:doi
1665:PMC
1657:doi
1610:doi
1606:223
1546:doi
1505:doi
1464:doi
1423:doi
1370:PMC
1362:doi
1309:doi
1268:doi
1264:107
1219:PMC
1211:doi
1167:PMC
1159:doi
1155:142
1118:doi
1114:360
1071:doi
1059:296
1033:PMC
1025:doi
1021:325
1017:BMJ
965:doi
905:doi
867:doi
827:doi
780:doi
399:FDA
240:in
2732::
2690:.
2682:.
2670:.
2646:.
2634:73
2632:.
2628:.
2605:.
2595:.
2583:10
2581:.
2577:.
2554:.
2546:.
2534:87
2532:.
2528:.
2505:.
2491:.
2487:.
2464:.
2456:.
2444:.
2420:.
2410:.
2398:.
2394:.
2371:.
2363:.
2353:48
2351:.
2328:.
2316:53
2314:.
2310:.
2287:.
2277:.
2265:62
2263:.
2259:.
2236:.
2228:.
2216:.
2193:.
2185:.
2173:16
2171:.
2167:.
2144:.
2132:54
2130:.
2126:.
2103:.
2091:63
2089:.
2085:.
2062:.
2050:24
2048:.
2044:.
2021:.
2011:.
2001:31
1999:.
1995:.
1972:.
1960:12
1958:.
1954:.
1931:.
1919:34
1917:.
1913:.
1890:.
1878:32
1876:.
1872:.
1849:.
1835:.
1831:.
1808:.
1798:.
1788:27
1786:.
1782:.
1759:.
1749:.
1737:.
1714:.
1702:21
1700:.
1696:.
1673:.
1663:.
1653:67
1651:.
1647:.
1624:.
1616:.
1604:.
1579:12
1577:.
1554:.
1542:32
1540:.
1536:.
1513:.
1501:30
1499:.
1495:.
1472:.
1460:27
1458:.
1454:.
1431:.
1419:63
1417:.
1413:.
1378:.
1368:.
1358:14
1356:.
1352:.
1317:.
1305:36
1303:.
1299:.
1276:.
1262:.
1258:.
1235:.
1227:.
1217:.
1207:59
1205:.
1201:.
1189:^
1175:.
1165:.
1153:.
1149:.
1126:.
1112:.
1108:.
1085:.
1077:.
1069:.
1057:.
1031:.
1019:.
1015:.
973:.
961:91
959:.
955:.
919:.
911:.
899:.
887:^
873:.
861:.
849:^
835:.
823:87
821:.
817:.
794:.
786:.
776:89
774:.
748:23
746:.
720:.
634:.
623:^
561:.
539:.
517:.
426:.
389:.
248:.
244:,
225:.
205:.
201:,
182:.
126:,
112:,
108:,
60:,
49:)
2718:.
2698:.
2678::
2654:.
2640::
2613:.
2589::
2562:.
2540::
2513:.
2499::
2493:5
2472:.
2452::
2428:.
2406::
2379:.
2359::
2336:.
2322::
2295:.
2281::
2271::
2244:.
2224::
2218:1
2201:.
2179::
2152:.
2138::
2111:.
2097::
2070:.
2056::
2029:.
2007::
1980:.
1966::
1939:.
1925::
1898:.
1884::
1857:.
1843::
1816:.
1794::
1767:.
1753::
1745::
1739:5
1722:.
1708::
1681:.
1659::
1632:.
1612::
1589:.
1562:.
1548::
1521:.
1507::
1480:.
1466::
1439:.
1425::
1386:.
1364::
1325:.
1311::
1284:.
1270::
1243:.
1213::
1183:.
1161::
1134:.
1120::
1093:.
1073::
1065::
1041:.
1027::
981:.
967::
927:.
907::
901:2
881:.
869::
863:2
843:.
829::
802:.
782::
758:.
730:.
706:.
685:.
665:.
645:.
593:.
575:.
553:.
531:.
45:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
